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Phenothiazine-mediated rescue of cognition in
tau transgenic mice requires neuroprotection and
reduced soluble tau burden
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Umesh K Jinwal1, John Koren III1, Jeffrey R Jones1, Clara Kraft1, Melinda Peters2, Jose F Abisambra1, Karen E Duff4,
Edwin J Weeber2, Jason E Gestwicki3, Chad A Dickey1*
Abstract
Background: It has traditionally been thought that the pathological accumulation of tau in Alzheimer’s disease
and other tauopathies facilitates neurodegeneration, which in turn leads to cognitive impairment. However, recent
evidence suggests that tau tangles are not the entity responsible for memory loss, rather it is an intermediate tau
species that disrupts neuronal function. Thus, efforts to discover therapeutics for tauopathies emphasize soluble tau
reductions as well as neuroprotection.
Results: Here, we found that neuroprotection alone caused by methylene blue (MB), the parent compound of the
anti-tau phenothiaziazine drug, Rember™, was insufficient to rescue cognition in a mouse model of the human
tauopathy, progressive supranuclear palsy (PSP) and fronto-temporal dementia with parkinsonism linked to
chromosome 17 (FTDP17): Only when levels of soluble tau protein were concomitantly reduced by a very high
concentration of MB, was cognitive improvement observed. Thus, neurodegeneration can be decoupled from tau
accumulation, but phenotypic improvement is only possible when soluble tau levels are also reduced.
Conclusions: Neuroprotection alone is not sufficient to rescue tau-induced memory loss in a transgenic mouse
model. Development of neuroprotective agents is an area of intense investigation in the tauopathy drug discovery
field. This may ultimately be an unsuccessful approach if soluble toxic tau intermediates are not also reduced. Thus,
MB and related compounds, despite their pleiotropic nature, may be the proverbial “magic bullet” because they
not only are neuroprotective, but are also able to facilitate soluble tau clearance. Moreover, this shows that
neuroprotection is possible without reducing tau levels. This indicates that there is a definitive molecular link
between tau and cell death cascades that can be disrupted.
Background
The current clinically available options for treating Alz-
heimer’s disease (AD) are limited to acetylcholinesterase
inhibitors and NMDA receptor antagonists [1,2]. For
tauopathies like PSP and FTDP17, treatment is
restricted to supportive therapies. Thus the demand to
identify compounds that can remove the microtubule
associated protein tau is extremely high.
Modifying tau patho-physiology has been the primary
goal of first-generation tau therapeutics. For example,
kinase inhibitors [3], microtubule stabilizers [4], tau
aggregation inhibitors, immunotherapy [5], and chaper-
one-based drugs targeting disease-specific tau species
[6], have all been proposed based largely on in vitro
data. However, their efficacy for ameliorating cognitive
deficits in mouse models of tauopathy have not been
tested, primarily due to the fact that few models of tau
accumulation are available that develop memory loss.
One of the more controversial tau modifying com-
pounds, to recently emerge as a potentially clinically
relevant drug, is the phenothiazine methylthionium
chloride better known as methylene blue (MB). MB is
best known for its function in the laboratory as a redox
indicator and as an antiseptic [7]; however, it, along
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with other phenothiazine derivatives, have been used
extensively in the clinic since the 1950’s to treat a num-
ber of different conditions, including schizophrenia,
mania, anxiety, emesis, cancer, high blood pressure,
allergies and even parasitic infections [8]. These com-
pounds are generally well tolerated and have minimal
side effects, including discoloration of urine and ocular
vitreous.
More recently MB has been shown to inhibit the
aggregation propensity of proteins that can adopt a b-
sheet conformation in vitro [9-11], and it was this prop-
erty that critically linked MB to AD as a possible plaque
or tangle buster. However, the propensity of the phe-
nothiazines to liberally bind to proteins and donate elec-
trons has resulted in a number of other mechanisms
being ascribed to them. For example, MB can regulate
mitochondrial function [12,13] and inhibit Hsp70
ATPase activity [14,15].
Interestingly, these pleiotropic mechanisms and clini-
cal applications combined with their relatively innocu-
ous side effects and high bioavailability are what make
the phenothiazines such an interesting therapeutic
option for tauopathies. Most of the outcomes ascribed
to MB could converge to ameliorate symptoms asso-
ciated with tau accumulation. Here, we sought to deter-
mine whether MB could potentially be beneficial as a
therapeutic option for tauopathies based on its pleiotro-
pic anti-tau efficacy, we investigated how its chronic
administration might impact the rTg4510 tau transgenic
mice. We show that MB is capable of protecting neu-
rons, however, only high dose MB treatment was able to
reduce tau and also improve cognition. However,
pathology was unaffected. This shows that MB does not
reduce tau pathology, but reduces soluble tau levels.
Also, it shows that neuroprotection alone is not suffi-
cient to improve behavior, but only when MB levels are
sufficiently high to reduce soluble tau levels can mem-
ory be improved.
Results and Discussion
Previously, biochemical analyses of hippocampal tissue
from tau transgenic mice (rTg4510; [16]) injected with
MB showed reduced tau levels after 24 hours [15].
Hippocampi of wildtype mice were then injected with
either 1 mM or 0.1 mM MB (based on a recent study in
Zebrafish [17]) to determine its effective therapeutic
window for reducing tau levels. Only 1 mM MB reduced
tau levels (Figure 1A). Based on these results, 1 mM MB
(1 mM; n = 6) or saline (n = 7) was administered to the
right hippocampi [18] of 7-month old rTg4510 mice for
1 month using mini-osmotic pump implantation (Figure
1B). The accumulation of soluble mutant human tau in
the forebrain of this model causes spatial memory defi-
cits as early as 3 months of age, which precede neuronal
loss [16]. Morris water maze (MWM) during the final
week of treatment revealed that MB-treated mice
showed significant improvements in learning the loca-
tion of the escape platform compared to those receiving
saline (Figure 1C). Probe trial analysis using target quad-
rant discrimination, number of platform crossings and
search strategy imaging showed significantly improved
cognitive recall in MB-treated mice compared to those
treated with saline (Figure 1D-F). Biochemical analysis
of hippocampal lysates showed that both phosphorylated
(S202/T205) and total tau levels were significantly
reduced (Figure 2A,B). Thus, despite the focal distribu-
tion of osmotic pump administration and the age of the
mice, MB was still able to improve cognitive function;
an effect that was concomitant with reductions in hip-
pocampal tau levels. Contrastingly, pathology was unaf-
fected (Figure 2C,D). Furthermore, nissl staining was
done in order to determine if any damage was done to
the hippocampus due to pump implantation. No such
damage was found (Figure 2E,F).
Based on this evidence, a new trial was initiated in
rTg4510 mice to test the effects of long-term MB
administration not only on behavior and tau biochemis-
try, but also on neuronal survival and tau pathology.
Practical limitations with osmotic pump applications
required that this study be done using non-invasive per-
ipheral administration. Dose selection for this study was
based on two factors: 1) FDA conversion tables show
that a 10 mg/kg dose in a mouse is equivalent to ~1
mg/kg in humans, which is within the range of current
MB clinical applications [19,20], and 2) pharmacokinetic
analyses showed that MB could concentrate in the brain
500-fold, making the effective concentration. (> 100
μM) possible(Figure 3A,B)
Thus, two groups (n = 10) of 3 month-old rTg4510
mice and two groups of 10 wildtype littermates received
either ~10 mg/kg(165 μM; 5× maximum recommended
dose) of MB via drinking water supplemented with 2
mM saccharine or saccharine water alone (Figure 4A).
Following 12 weeks of treatment, behavioral assessment
showed no overt alterations in motor coordination or
task acquisition (See additional file 1: Figure 1). MWM
was then used to assess cognitive function. Probe trial
analysis and search strategy imaging showed that MB,
but not saccharine, prevented the significant progressive
impairment in target quadrant discrimination that is a
hallmark of the rTg4510 phenotype (Figure 4B,C).
Furthermore, wildtype littermates showed normal spatial
memory recall irrespective of MB treatment. Biochem-
ical analyses of half-brain homogenates (excluding cere-
bellum) showed a reduction in soluble tau levels in
some mice, but not others (Figure 5A,B). Histochemical
analyses revealed no change in tau pathology in any
mice (Figure 5C,D).
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Figure 1 Direct hippocampal infusion of methylene blue by mini-osmotic pump reverses spatial navigation related learning and
memory deficits by reducing tau levels in rTg4510 mice. (A) Four groups of wildtype mice (n = 3) were injected with 100 μM MB, 1 mM
MB, or saline into the hippocampus for 24 hours. Western blot from hippocampal lysates show reductions in tau at 1 mM MB in phospho- and
total tau. (B) Experimental design of central administration of MB (MB central n = 6, saline central n = 7). (C) Infusion of MB increased ability of
rTg4510 mice to learn the location of the hidden platform in the MWM, **p < 0.01). (D) Probe trial of Morris water maze shows that MB treated
rTg4510 mice were able to recognize the target from the opposite quadrant, unlike saline treated rTg4510 mice, (F(3,20) = 8.202, p = 0.0009),
***p < 0.001. (E) Number of crossing across the area where the hidden platform was located during training. (F(7, 44) = 2.757, p = 0.0183), p <
0.05. (F) Search strategy imaging using a camera tracking system shows that MB treated rTg4510 mice have a more focused strategy than saline
treated rTg4510 mice.
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Figure 2 MB treatment reduces tau levels, but does not affect pathology in mice with pre-existing tangle formation and
neurodegeneration. (A) Western blot analysis of tau protein levels from hippocampal lysates. (B) Quantitation of the optical density as a
percentage of saline treated rTg4510 mice shows a significant difference in pS202/T205 and total tau levels, *p < 0.05. (C) Representative images
of the gallyas silver stain. Scale bar, 200 μm. (D) High magnification images of the gallyas silver stain. Scale bar, 20 μm. (E) Percentage of area of
silver positive staining shows no statistical difference between the means (n = 2 per group). (F) Representative images of the staining of
neuronal nissl substance in the ipsilateral side of drug infusion (right hippocampus). Scale bar, 200 μm. (G) Quantitation of the percent area
positive for nissl staining of ipsilateral versus the contralateral brain side of each group of mice shows that there is no detectable neuron loss
due to pump implantation.
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Given the variability in behavioral performance as well
as reductions in tau levels, we hypothesized that the MB
concentration in the brain may have also varied due to
the ad libitum administration strategy. To test this idea,
brain concentrations of MB were assessed using LC-MS
analysis of the cerebellar tissue from these mice. Indeed,
MB concentration was positively correlated with MWM
performance (p < 0.05) and was inversely correlated
with soluble tau levels (p < 0.05) (Figure 6A,B). The dif-
ferences in brain MB concentration between mice could
not be attributed to body weight or gender (See addi-
tional file 1: Figure 2). Moreover, mice with >470 μM
MB brain concentration accounted for a preponderance
of the effects on memory function and tau reductions,
consistent with our previous results showing that very
high concentrations of MB were required for anti-tau
efficacy (Figure 1A). Surprisingly, stereological assess-
ment of five different brain regions from these mice
showed that MB treatment significantly delayed neuro-
degeneration by ~30% in all forebrain regions of all
rTg4510 mice (Figure 6C), but neuronal number failed
to correlate with memory performance or soluble tau
levels (Figure 6D and data not shown).
Post-hoc analysis of the behavioral performances of
rTg4510 mice with brain MB concentrations above or
below ~470 μM (High [MB] or Low [MB], respectively),
elucidated that the High [MB] cohort performed equiva-
lent to wildtype mice, while the Low [MB] cohort was
significantly impaired (Figure 7A). We again used the
camera-tracking software to map the areas of the pool
most traversed by each cohort (Figure 7B). High [MB]
rTg4510 mice were predominantly found in the target
quadrant, while the Low [MB] cohort displayed an
unguided search strategy. Furthermore, we wanted to
see if MB treatment in the High [MB] mice had an
effect on motor learning. The mice were subjected to
the rotorod task for two days and the latency to fall
onto a spring-cushioned lever was measured. We found
that motor learning from day 1 to day 2 of MB treated
rTg4510 was significantly improved, dissimilar to the
saccharine treated rTg4510 analogs (Figure 7C).
Conclusions
In conclusion, these findings are consistent with recent
evidence showing that reducing tangle burden does not
beget functional recovery [16,21,22]; however, the unex-
pected result that neuroprotection is insufficient to pre-
serve cognitive function suggests that preventing
neuronal loss may not be enough to alter cognitive defi-
cits in tauopathies either. In fact, it was only when solu-
ble tau levels are reduced in the brain that functional
recovery was observed. Moreover, these data show that
there is a link between tau and cell death signaling cas-
cades that can be altered with therapeutics since neuro-
degeneration can be decoupled from tau accumulation
with MB.
Materials and methods
Mice
The rTg4510 mice and parental mutant tau and tTA
lines were generated and maintained for this study as
previously described [16].
Central Administration
A concentration of 1 mM MB in saline was infused by
pump into the CA3 of the right hippocampus of
rTg4510 mice. Alzet pumps (Model 1004, 100 μL, 0.11
μl/hr; Alzet Osmostic Pumps) were filled with 100 μl of
Figure 3 Pharmacokinetic analysis of MB following peripheral administration. (A) A single intravenous (I.V.) administration of 20 mg/kg MB
was given to wildtype mice at different time points (n = 3 per time point), and cerebellar and plasma concentrations were measured through
LC-MS. (B) A single 200 mg/kg oral gavage bolus of MB was given to wildtype mice at different time points (n = 3 per time point) and also
measured by LC-MS. Cerebellar brain concentrations of MB are higher than plasma.
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1 mM MB or with saline 0.9%. The pumps were incu-
bated in 0.9% saline at 37°C for 48 hrs. Mice were oper-
ated on a stereotaxic apparatus (51725 D, Stoelting,
Wood Dale, IL). A midsagittal incision was made to
expose the cranium and a small aperture was drilled
with a dental tool over the right hippocampus to the fol-
lowing coordinates from bregma: anterior-posterior, -2.7
mm; lateral, -2.5 mm. The osmotic pump was inserted
into a subcutaneous pocket on the back of the mouse,
leading the catheter to the site of cannula (Brain infu-
sion kit 3, Alzet) placement. The cannula, with a thin
layer of cyanoacrylate (Loctite 454, Alzet), was attached
to the stereotaxic cannula holder (Cannula holder
51636, Stoelting) and then lowered 3 mm ventral
through the midline aperture. The incision was cleaned
with saline and closed with surgical sutures. After sur-
gery, the mice were housed individually. Infusion lasted
for 28 days. Six mice were administered with MB and 7
with Saline. The mice were 7 months old at the time of
surgery and they were 7 months and three weeks old at
the time of water maze testing.
Peripheral administration
Ten age and gender-matched rTg4510 mice and ten
wildtype littermates were administered MB (Sigma) and
saccharine (Acros Organics, Geel, Belgium) in their
Figure 4 Chronic treatment with methylene blue has moderate effect in behavior. (A) Experimental design, n = 10. (B) Percent of time
spent in each quadrant during the probe trial of MWM (F(15,144) = 8.781, p < 0.0001). MB rTg4510 recognize target versus opposite quadrant (F
(3,36) = 3.38, p = 0.0286), *p < 0.05. (C) Search strategy imaging using a camera tracking system.
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Figure 5 Chronic dosing of methylene blue leads to reductions in soluble tau but pathology is unaffected. (A) Half-brain lysates (no
cerebellum) were analyzed for tau protein levels by Western blot. (B) Optical density of tau levels is shown as a percentage of control
(saccharine treated rTg4510), *p < 0.05. (C) Representative images of immunoreactivity to a phosphorylated tau epitope (pS202/T205), the MC1
epitope (early tangles), and reactivity to the gallyas silver stain (late tangles) are shown. Scale bar, 200 μm. (D) High magnification images of
immunohistochemistry. Scale bar, 20 μm. (E) Quantitation of the percent area of positive staining shows no statistical significance between the
means of all stains.
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drinking water, while another ten rTg4510 mice and ten
wildtype littermates received drinking water with sac-
charine only. A treatment of 650 mg/day in a 70 kg
human equates to 9.3 mg/kg/day. Based on a 4.5 ml of
water/day rate of consumption of a 30 g mouse, ad libi-
tum, we estimated mice to receive 9.3 mg/kg/day (0.062
mg/ml). MB or vehicle administration was initiated in 12
week-old rTg4510 and wildtype mice using drinking
water supplemented with 2 mM saccharine. Treatment
was maintained for four months and the supplemented
water was replaced three times per week. Mice were 6
months old at the time of initial behavioral assessment
and they were 6.5 months old at the time of the water
maze analysis. During the course of the study one mouse
died of unknown circumstances and drug, tau levels and
stereological analyses were not able to measured.
Determination of Methylene Blue Concentrations in the
Cerebellum
Frozen brain tissue was thawed on ice and homogenized
for 2 minutes at a concentration of 100 mg/ml in
homogenizing solution (ACN:PBS = 9:1). A 30 μL ali-
quot of the brain homogenate was added to a 1.5 mL
polypropylene microcentrifuge tube and spiked with 30
μL of the internal standard solution (Methylene Violet
3RAX, 250 ng/ml). Analytical grade acetonitrile was
then added (90 μL) and the sample was vortexed again
for 30 s. Following highspeed centrifugation at 13,200
rpm for 10 minutes at 4°C, the supernatant was trans-
ferred to a glass vial and subjected to LC-MS analysis.
The LC-MS system used for these studies was a Shi-
madzu (Columbia, MD) series 2010EV instrument
equipped with an APCI probe to minimize ion suppres-
sion. Quantification was performed using LCMSolution
Version 2.05 and a set of external standards.
Behavioral Analysis
Open Field
The open field is used as a standard test of general
activity. Animals are monitored for 15 minutes in a 40
cm square open field with a video tracking software
(ANY-Maze, Stoelting, Illinois), under moderate lighting.
Figure 6 Chronic dosing of methylene blue enhances neuronal survival. (A) Parenchymal drug concentrations correlated significantly with
memory retention in the probe trial of MWM p = 0.016, Pearson r = 0.766, r2 = 0.587. (B) Tau levels inversely correlate significantly with
parenchymal drug concentration, p < 0.05, Pearson r = -0.6724, r2 = 0.452. (C) Number of neurons counted in five regions as a percentage of
sacc treated rTg4510 (MB treated rTg4510 n = 8, sacc treated rTg4510 n = 10) (DG stands for dentate gyrus, CX stands for cortex and STR stands
for striatum). (D) Number of neurons does not correlate significantly with time spent in the target quadrant.
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General activity levels were evaluated by measurements
of horizontal and vertical activity.
Rotorod test
This test was performed on an accelerating rotorod
apparatus (Ugo Basile, Italy) with a 3 cm diameter rod
starting at an initial rotation of 4 RPM accelerating to
40 RPM over 5 minutes. Mice were tested for the time
spent on the rod during each of four trials with a thirty-
minute inter-trial interval. Each trial was completed
when the mouse fell off the rod (distance of 12 cm)
onto a spring-cushioned lever.
Elevated Plus Maze
Anxiety can be assessed through the elevated plus maze
(EPM). The EPM consisted of two well-lit open arms
(35 cm) facing each other and two enclosed arms (30.5
cm) also facing each other. Each arm is attached to a
common center platform (4.5 cm square) and elevated
40 cm off the floor. The mouse was placed in the center
platform and allowed to explore for 5 min. Video track-
ing software measured movement in each section
(ANY-Maze, Stoelting, Illinois).
Morris Water Maze
The Morris water maze (MWM) consisted of a circular
pool (1.38-m diameter) filled with opaque water at room
temperature with an escape platform (15 cm × 15 cm)
hidden beneath the water level (3 cm). Each mouse was
given four trials per day with an inter-trial interval of 1
hour for 6 consecutive days. The time to find the
Figure 7 High concentrations of MB repair spatial and motor memory deficits. (A) (A)Post-hoc analyses reveal that High [MB] rTg4510 mice
(n = 5) perform similar to wild-type MB treated mice, while Low [MB] rTg4510 mice (n = 4) did not display memory retention. Wildtype mice
performed similarly regardless of MB (F(7,30) = 10.64, p < 0.0001), **p < 0.01, ***p < 0.001. (B) Camera tracking software imaging of MB treated
rTg4510 mice divided by low and high parenchymal MB concentrations. (C) Motor learning was assessed by comparing the average latency to
fall from the rotorod apparatus of day 1 with the average of day 2. High [MB] rTg4510 mice (n = 5) learn better than saccharine treated rTg4510
(n = 10). Wildtype groups, n = 10, **p < 0.01, ***p < 0.001.
O’Leary et al. Molecular Neurodegeneration 2010, 5:45
http://www.molecularneurodegeneration.com/content/5/1/45
Page 9 of 11
platform (escape latency), the total distance traveled and
the swim speed of the animals was recorded. Each ani-
mal was given a maximum of 60 seconds to find the
platform. During training, if the mice failed to find the
platform after 60 seconds, they were placed on the plat-
form for 30 seconds. They were then towel-dried and
placed in a cage with a heating pad underneath until
dry and returned to their home cage. On day 7 the mice
were subject to one probe trial in which the platform
was removed and each animal had 60 seconds to search
the training pool for the platform.
Brain Tissue Fractionation and Western Blot Analysis
Brain tissue was homogenized as previously described
[23]. Measurements of tau levels were performed by
western blot analysis.
Immunohistochemistry
Fixed mouse brains were cryoprotected in successive 24
hours incubations of 10%, 20%, and 30% solutions of
sucrose and then sectioned as previously described [Gor-
don, 2002]. Stained sections were imaged using an Olym-
pus BX51 microscope at original 40×, 100×, or 200× final
magnification. For quantification, images (original 100×
magnification) of cornu ammonis (CA)1, CA3, entorhinal
cortex, cortex and dentate gyrus were taken using spatial
orientation cues. Quantification of positive staining pro-
duct was determined using Image-Pro Plus (Media
Cybernetics, Silver Springs, MD). Nissl staining was done
in 0.05% cresyl violet for 5 minutes followed by differen-
tiation in acidic water until desired color. Tissue was
dehydrated through a graded series of ethanol (75%, 95%
and 100%). Slides were cleared in Histoclear (xylene sub-
stitute) and coverslipped with DPX. Silver stain was per-
formed as previously described [24].
Stereological analysis
Neurons that were stained with cresyl violet were
counted in the the cornu ammonis 1 (CA1), the cornu
ammonis 2 and 3 (CA2+3), the dentate gyrus (DG), the
cerebral cortex (CX) and the striatum (STR) using the
optical fractionator method of stereological counting
[25] with commercially available stereological software
(StereoInvestigator, MBF Bioscience, Williston, VT). A
systematic random sampling of sections throughout the
left hemibrain were stained as described above and
coded to ensure blinding. The regions of interests (ROI)
were defined using specific landmarks within the brain
to maintain consistency. A grid was placed randomly
over the ROI slated for counting. At regularly predeter-
mined positions of the grid, cells were counted within
three-dimensional optical dissectors. Within each dissec-
tor, a 1 μm guard distance from the top and bottom of
the section surface was excluded. Section thickness was
measured regularly on all collected sections to estimate
the mean section thickness for each animal after tissue
processing and averaged 35.24 μm ± 0.46 μm for all sec-
tions analyzed. The total number of neurons was calcu-
lated using the equation:
N = Q 1/ssf 1/asf 1/hsf- × × ×
where N is total neuron number, Q- is the number of
neurons counted, ssf is section sampling fraction, asf is
the area sampling fraction and hsf is the height sam-
pling fraction. Tissue from one mouse in the MB-trea-
ted rTg4510 cohort was unusable for this study.
Therefore, n = 8 for this group.
Antibodies
Tau antibodies S202/T205, MC1 and PHF-1 were pro-
vided by Dr. Peter Davies, Albert Einstein College of Med-
icine; total tau antibody was purchased from Stantacruz
Biotech, Stantacruz, CA. Horseradish peroxidase conju-
gated secondary antibodies were obtained from Southern
Biotech, Birmingham, AL. Glyceraldehyde-3-phosphate
dehydrogenase antibody was obtained from Meridian Life
Science, Saco, ME. Actin antibody was obtained from
Sigma, St. Loius, MO. P-tau refers to PHF-1.
Statistical Analysis
Statistical analysis comparing 2 groups was done using
an unpaired, two tailed t-test. Analysis comparing more
than 2 groups was done using a one-way analysis of var-
iance (ANOVA) with the Tukey-Kramer post-hoc test.
Analysis of three or more groups during different time
points (water maze learning and rotorod) was done
using repeated measures 2-way ANOVA with the Bon-
ferroni post-hoc test. Statistical analysis was done in the
GraphPad Prism software.
Additional material
Additional file 1: Supplementary data on the administration of
methylene blue in rTg4510 mice. Additional data contains information
on the effect of chronic dosing of MB on behavior and statistical
comparisons between parenchymal drug concentration, gender, and
weight.
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